Last year the Institute for Alternative Futures published results from its updated diabetes (type 1 and type 2) forecasting model, extending its projections to 2030. The data show that diabetes will remain a major health crisis in the U.S., with the prevalence of diabetes increasing by 54 percent to more than 54.9 million people.
The growth of cell and gene therapies has been dramatic over the past 12 months, catalyzed by the FDA approval of three gene therapies last year. Since then the flood gates have opened and the field has attracted considerable attention from investors and industry alike.
BOSTON – Gene therapies have remained a tantalizing promise ever since the early 1990s, said Steve Bagshaw, CEO of Fujifilm Diosynth Biotechnologies, who was moderating a BIO 2018 panel on this exciting area. Now thanks to scientific advances, several product approvals, and significant business development and investments, expectations are once again high that the field has finally reached prime time and is ready to transform 21st century medicine.
BOSTON – In recent years there has been a significant shift in the research and development focus of large biopharmaceutical companies. They have become much more outward looking in order to source drug development projects that will help boost their existing product pipeline. It is not just late-stage programs that are on their radar screens because, according to Cortellis Deals Intelligence and BioWorld data, among the partnership deals entered into by the top companies last year, over half of them involved discovery stage assets.
BOSTON – At a press conference at the BIO International Conference, Alxerion Biotech Inc., a new Massachusetts Institute of Technology (MIT) biotech startup, discussed how it is developing new technologies to harness the therapeutic potential of exosomes, small lipid bilayer vesicles, which are part of the transportable cell secretome.
BOSTON – In 2012, the last time the BIO International Convention was held in Boston, Jim Greenwood, president and CEO of BIO, noted in a statement that "the overarching sentiment shared by the majority of attendees is a positive outlook for the future of our industry." His view was spot on because in the intervening five years the industry has been on a tear, with the Nasdaq Biotechnology Index recording a 155 percent jump in value. Fundraising has also been off the charts and business development has continued at a frenetic pace.
BOSTON – In 2012, the last time the BIO International Convention was held in Boston, Jim Greenwood, president and CEO of BIO, noted in a statement that "the overarching sentiment shared by the majority of attendees is a positive outlook for the future of our industry." His view was spot on because in the intervening five years the industry has been on a tear, with the Nasdaq Biotechnology Index recording a 155 percent jump in value. Fundraising has also been off the charts and business development has continued at a frenetic pace.
The evolution of the biotechnology industry has been mirrored in many respects by the growth of BIO's own meeting, which has expanded every year following the very first event hosted in Research Triangle Park, N.C., in 1993. BioWorld Insight takes a look back at those events and provides interesting statistics below on the evolution of the industry.
The BIO International Convention 2018 in Boston and the American Society of Clinical Oncology (ASCO) meeting in Chicago, two of the important events in the biotech sector's annual calendar, are almost upon us. With that in mind, BioWorld Asia dives into the business of financial aspects of cancer. There is no doubt that transformative cancer therapies have attracted the attention of everyone, particularly investors, since they first burst on the scene a few years ago.
The BIO International Convention 2018 in Boston and the American Society of Clinical Oncology (ASCO) meeting in Chicago, two of the important events in the biotech sector's annual calendar, are almost upon us. With that in mind, BioWorld Insight kicks off a BIO 2018 two-part feature diving into the business of financial aspects of cancer. There is no doubt that transformative cancer therapies have attracted the attention of everyone, particularly investors, since they first burst on the scene a few years ago.
